A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.

The journal of pathology. Clinical research Pub Date : 2022-09-01 Epub Date: 2022-06-27 DOI:10.1002/cjp2.285
Hiroyuki Takahashi, Hirono Watanabe, Miki Hashimura, Toshihide Matsumoto, Ako Yokoi, Mayu Nakagawa, Yu Ishibashi, Takashi Ito, Kensuke Ohhigata, Makoto Saegusa
{"title":"A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.","authors":"Hiroyuki Takahashi, Hirono Watanabe, Miki Hashimura, Toshihide Matsumoto, Ako Yokoi, Mayu Nakagawa, Yu Ishibashi, Takashi Ito, Kensuke Ohhigata, Makoto Saegusa","doi":"10.1002/cjp2.285","DOIUrl":null,"url":null,"abstract":"<p><p>Programmed cell death-1 (PD-1) and its ligand (PD-L1) are significant mediators of immune suppression in the tumor microenvironment. We focused on the immunological impact of PD-1/PD-L1 signaling during tumor progression in colorectal carcinoma (CRC) and its association with resistance to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal carcinoma (LAd-RC). Histopathological and immunohistochemical analyses of 100 CRC cases (including 34 RC) without NCRT and 109 NCRT-treated LAd-RC cases were performed. Membranous tumoral PD-L1 expression was identified in 9 of 100 (9%) CRC cases, including 1 of 34 (2.9%) RC cases, but PD-L1 immunopositivity was not associated with any clinicopathological factors, with the exception of deficient mismatch repair (dMMR) status. In contrast, stromal PD-L1+ immune cells, which frequently exhibited coexpression of PD-1 and CD8 markers, were significantly correlated with tumor vessel invasion, nuclear β-catenin+ tumor budding cancer stem cell (CSC)-like features, and unfavorable prognosis. In the LAd-RC cases, stromal CD8+ (but not PD-L1+) immune cell infiltration in pretreatment-biopsied samples was significantly and positively associated with therapeutic efficacy. After NCRT, tumoral PD-L1 expression was observed in only 2 of 83 (2.4%) tumors, independent of dMMR status, whereas high stromal PD-L1+ and tumoral nuclear β-catenin positivity were significantly linked to a poor response to NCRT and high tumor budding features. In addition, high stromal PD-L1 immunoreactivity was significantly associated with poorer overall survival. In conclusion, a combination of stromal PD-L1+ immune cells and nuclear β-catenin+ tumor budding may contribute to tumor progression in CRC and resistance to NCRT in LAd-RC, through formation of niche-like lesions that exhibit immune resistance and CSC properties.</p>","PeriodicalId":151537,"journal":{"name":"The journal of pathology. Clinical research","volume":" ","pages":"458-469"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353658/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of pathology. Clinical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cjp2.285","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Programmed cell death-1 (PD-1) and its ligand (PD-L1) are significant mediators of immune suppression in the tumor microenvironment. We focused on the immunological impact of PD-1/PD-L1 signaling during tumor progression in colorectal carcinoma (CRC) and its association with resistance to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal carcinoma (LAd-RC). Histopathological and immunohistochemical analyses of 100 CRC cases (including 34 RC) without NCRT and 109 NCRT-treated LAd-RC cases were performed. Membranous tumoral PD-L1 expression was identified in 9 of 100 (9%) CRC cases, including 1 of 34 (2.9%) RC cases, but PD-L1 immunopositivity was not associated with any clinicopathological factors, with the exception of deficient mismatch repair (dMMR) status. In contrast, stromal PD-L1+ immune cells, which frequently exhibited coexpression of PD-1 and CD8 markers, were significantly correlated with tumor vessel invasion, nuclear β-catenin+ tumor budding cancer stem cell (CSC)-like features, and unfavorable prognosis. In the LAd-RC cases, stromal CD8+ (but not PD-L1+) immune cell infiltration in pretreatment-biopsied samples was significantly and positively associated with therapeutic efficacy. After NCRT, tumoral PD-L1 expression was observed in only 2 of 83 (2.4%) tumors, independent of dMMR status, whereas high stromal PD-L1+ and tumoral nuclear β-catenin positivity were significantly linked to a poor response to NCRT and high tumor budding features. In addition, high stromal PD-L1 immunoreactivity was significantly associated with poorer overall survival. In conclusion, a combination of stromal PD-L1+ immune cells and nuclear β-catenin+ tumor budding may contribute to tumor progression in CRC and resistance to NCRT in LAd-RC, through formation of niche-like lesions that exhibit immune resistance and CSC properties.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
间质PD-L1和肿瘤核β-catenin联合表达作为局部晚期直肠癌进展和放化疗耐药的指标
程序性细胞死亡-1 (PD-1)及其配体(PD-L1)是肿瘤微环境中免疫抑制的重要介质。我们重点研究了PD-1/PD-L1信号在结直肠癌(CRC)肿瘤进展过程中的免疫学影响及其与局部晚期直肠癌(LAd-RC)新辅助放化疗(NCRT)耐药性的关系。对100例未行NCRT的结直肠癌(包括34例RC)和109例经NCRT治疗的ladc -RC进行了组织病理学和免疫组织化学分析。膜性肿瘤PD-L1表达在100例(9%)CRC病例中有9例,包括34例(2.9%)RC病例中有1例,但PD-L1免疫阳性与任何临床病理因素无关,除了缺陷错配修复(dMMR)状态。相反,基质PD-L1+免疫细胞经常表现出PD-1和CD8标记物的共表达,与肿瘤血管侵袭、核β-catenin+肿瘤出芽癌干细胞(CSC)样特征和不良预后显著相关。在LAd-RC病例中,预处理活检样本中基质CD8+(而非PD-L1+)免疫细胞浸润与治疗效果显著正相关。在NCRT后,83例肿瘤中只有2例(2.4%)的肿瘤PD-L1表达,与dMMR状态无关,而高间质PD-L1+和肿瘤核β-catenin阳性与对NCRT的不良反应和高肿瘤出芽特征显著相关。此外,高间质PD-L1免疫反应性与较差的总生存率显著相关。综上所述,基质PD-L1+免疫细胞和细胞核β-catenin+肿瘤出芽的结合可能通过形成具有免疫抗性和CSC特性的利基样病变,促进CRC的肿瘤进展和LAd-RC对NCRT的耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma. The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. Paediatric BCOR-associated sarcomas with a novel long spliced internal tandem duplication of BCOR exon 15. PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1